All In Biotech

Drug Trial Radar · NCT00413699

Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

A Long-term, Open-label Follow-up Study Of Tofacitinib (Cp-690,550) For Treatment Of Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Oct 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,488

Actual

Start

Feb 5, 2007

Primary completion

Nov 30, 2016

Study completion Oct 26, 2017

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 20, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another "qualifying" study of CP-690,550 A sub-study will be conducted within the A3921024 study, this study will evaluate the immune response to pneumococcal and influenza vaccines in patients receiving CP-690,550

Conditions

  • Arthritis, Rheumatoid

Interventions

  • CP-690,550Drug

    5 mg PO BID open label; may increase to 10 mg PO BID to provide greater control of RA if no related AEs are present. May be off study drug temporarily for up to 28 days for mild to moderate AEs.

  • CP-690,550Drug

    10 mg PO BID open label; may decrease to 5 mg PO BID for mild to moderate AEs. May be off study drug temporarily for up to 28 days for mild to moderate AEs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) ReportsTime frame: Includes laboratory test abnormality data for all visits and adverse event data up to 999 days after last dose of study drug
  2. Extension Period: Number of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs)Time frame: Baseline (Day 1 at Entry of Extension Period) up to 28 days after last study drug dose in Extension Period (13 Months)
  3. Extension Period: Number of Participants With Laboratory Test AbnormalitiesTime frame: Baseline (Day 1 at Entry of Extension Period) up to 28 days after last study drug dose in Extension Period (13 Months)
  4. Initial Period: The Long Term Safety and Tolerability of CP-690,550 5 Milligrams (mg) Twice Daily (BID) and 10 mg BID for the Treatment of Rheumatoid ArthritisTime frame: Includes AEs for every visit and up to 999 days after last dose of study drug
  5. Extension Period: Percentage of Participants With Adverse Events and Who Discontinued Treatment Due to Adverse Events to Assess Long-term Safety and Tolerability of TofacitinibTime frame: Baseline (Day 1 at Entry of Extension Period) up to Month 6 of Extension Period; Month 6 of Extension Period to Month 12 of Extension Period

Locations

469 sites in 43 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Rheumatology Associates of North Alabama, PC

    Huntsville, Alabama

  • Arthrocare, Arthritis Care & Research, PC

    Gilbert, Arizona

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Phoenix, Arizona

  • Radiant Research, Inc.

    Scottsdale, Arizona

  • Catalina Pointe Clinical Research

    Tucson, Arizona

  • CHI St. Vincent Medical Group Hot Springs

    Hot Springs, Arkansas

  • NEA Baptist Clinic

    Jonesboro, Arkansas

  • Osborne Research Center, LLC

    Little Rock, Arkansas

  • Little Rock Diagnostic Clinic, PA

    Little Rock, Arkansas

  • Med Investigations, Inc.

    Fair Oaks, California

  • Talbert Medical Group

    Huntington Beach, California

  • University of California San Diego Center for Innovative Therapy

    La Jolla, California

  • Keck Medicine of USC

    Los Angeles, California

  • University of Southern California (USC) Norris Comprehensive Cancer Center-

    Los Angeles, California

  • University of Southern California (USC) Norris Comprehensive Cancer Center

    Los Angeles, California

  • Ronald Reagan UCLA Medical Center, Drug Information Center

    Los Angeles, California

  • University of California Los Angeles

    Los Angeles, California

  • Stanford University School of Medicine

    Palo Alto, California

  • Office of Anupama Bhat, MD

    Roseville, California

  • San Diego Arthritis Medical Clinic

    San Diego, California

  • Pacific Arthritis Center Medical Group

    Santa Maria, California

  • Stanford Health Services - Medical Specialty Clinics

    Stanford, California

  • Inland Rheumatology Clinical Trials, Inc.

    Upland, California

  • Boulder Medical Center, PC

    Boulder, Colorado

  • Arthritis Associates and Osteoporosis Center of Colorado Springs

    Colorado Springs, Colorado

  • University of Connecticut Health Center

    Farmington, Connecticut

  • Arthritis & Osteoporosis Center, PC

    Hamden, Connecticut

  • New England Research Associates, LLC

    Trumbull, Connecticut

  • Delaware Arthritis and Osteoporosis Center

    Newark, Delaware

  • Arthritis and Rheumatic Disease Specialties

    Aventura, Florida

  • Allergy, Asthma, Arthritis, & Lung

    Daytona Beach, Florida

  • Physicians Research Alliance LLC

    DeBary, Florida

  • Southeastern Arthritis Center

    Gainesville, Florida

  • Southeastern Imaging and Diagnostics

    Gainesville, Florida

  • Southeastern Integrated Medical PL d/b/a Florida Medical Research Institute

    Gainesville, Florida

  • Southeastern Integrated Medical, PL, d/b/a Florida Medical Research Institute

    Gainesville, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Florida Arthritis Center, P.L.

    Lake Mary, Florida

  • BayCare Outpatient Imaging at Bardmoor

    Largo, Florida

Showing 40 of 469 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.